BiOptix receives additional $1.4M in funding
Optical biodetection company BiOptix (Boulder, CO) has received an additional $1.4 million in financing from existing investors, which will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand.
Related: Advances in optical biodetection
Rick Whitcomb, BiOptix's CEO, explains that the company sees opportunity in the label-free marketplace, which is looking for a high-performance surface plasmon resonance (SPR) instrument at a "reasonable price." SPR measures refractive index changes in a sensor chip's gold surface due to a change in mass that occurs during a binding event.
The company has developed and patented a novel, ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance (ESPR), which pairs the high sensitivity of SPR with the high stability and lower noise of common-path interferometry.
-----
Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!